NCT06558981

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

The Role of Adjuvant Radiotherapy in High Risk Locally Advanced Differentiated Thyroid Cancer：a 1:1 Randomized Phase III Clinical Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 124 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 14 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.

Conditions

• Thyroid Cancer

Interventions

Type	Name	Description
RADIATION	Radiotherapy	Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.
OTHER	radioiodine treatment	RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.

Timeline

• Start date: 2024-07-11
• Primary completion: 2031-06-01
• Completion: 2031-06-01
• First posted: 2024-08-19
• Last updated: 2026-02-27

Locations

1 site across 1 country: China